Regulatory Press Releases
PILA PHARMA AB, announces API manufacturing milestone achieved and changes to organisation
Malmö, Sweden, 04 February 2022 Download the press release as PDF here PILA PHARMA AB (PILA) today announces their first API manufacturing milestone has been successfully achieved. The manufacture of new XEN-D0501 API for the planned preclinical safety studies was, as announced 6 months ago, outsourced to Almac Group. The task to manufacture a critical API “starting material” was managed by…
PILA PHARMA AB, announces ink of agreement with pre-clinical service provider ERBC
Malmö, Sweden, 26 November 2021 Download the press release as PDF here PILA PHARMA AB (publ) announces that an agreement has been signed with the company ERBC, regarding the conduct of PILA PHARMA´s upcoming preclinical safety assessment studies. ERBC is a certified pre-clinical service provider, based in France and Italy. PILA PHARMA is, as previously announced, preparing a clinical phase…
PILA PHARMA AB skriver avtal med den prekliniska tjänstleveranören ERBC
Malmö, 26 november, 2021 Läs pressmeddelandet som PDF här PILA PHARMA AB (publ) meddelar att ett avtal har tecknats med företaget ERBC avseende genomförandet av PILA PHARMA:s kommande icke-kliniska toxikologiska studier. ERBC är en certifierad pre-klinisk tjänsteleverantör med säte i Frankrike och Italien. PILA PHARMA förbereder, som tidigare meddelats, en klinisk fas 2b-studie av läkemedelskandidaten XEN-D0501 mot diabetes typ 2.…
PILA PHARMA offentliggör delårsrapport för 1 juli – 30 september 2021
Malmö, 26 oktober 2021 Läs pressmeddelandet som PDF här PILA PHARMA AB (publ) (FN STO: PILA) publicerar i dag bolagets delårsrapport för perioden juli – september 2021 som finns att ta del av på bolagets hemsida: https://pilapharma.com/investors/finansiell-information/ SAMMANFATTNING AV DELÅRSRAPPORT Nio månader (1 januari – 30 september 2021) Rörelsens intäkter uppgick till 0 kSEK (0)Rörelseresultatet (EBIT) uppgick till - 6 180 kSEK…
PILA PHARMA publishes interim report for July 1 – September 30, 2021
Malmö, 26 October, 2021 Download the press release as PDF here PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s interim report for the period July – September 2021. The report can be found on the Company´s website: https://pilapharma.com/investors/finansiell-information/ SUMMARY OF INTERIM REPORT Nine months (1 January – 30 September 2021) Revenue was SEK 0 (0)Operating loss (EBIT) was SEK…